Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) in Patients With Haemorrhoids Undergoing Minimally Invasive Surgical Interventions

Inclusion Criteria:

* Males and females aged over 18 years.
* Informing the patient in writing about the inclusion in the study and his/her consent to participate in it.
* Absence of conditions requiring urgent medical care.
* The patient was diagnosed with chronic hemorrhoids of grade 2 or 3 according to Goligher classification.
* The patient is scheduled to undergo one of the listed types of minimally invasive surgical treatment within 7 ± 2 days from the inclusion in the study (V0):
* laser vaporization (laser submucosal destruction or ablation);
* transanal dearterialization (hemorrhoidal artery ligation);
* transanal dearterialization + laser vaporization (laser submucosal destruction or ablation);
* transanal dearterialization + sclerotherapy.
* No venoactive drug treatment within 4 weeks prior to inclusion in the study.
* The patient has been prescribed with MPFF at the inclusion visit, or it is planned to prescribe MPFF-containing drug in the postoperative period (for cluster 1 sites), or the patient has not been prescribed with any systemic venoactive drug, and it is not planned to prescribe it the postoperative period (for cluster 2 sites).\*

Exclusion Criteria:

* Pregnancy or breast-feeding, or planning for pregnancy during the study or at least in two months after its completion.
* Confirmed or suspected malignancy.
* Severe somatic disorder (of heart or blood vessels, lungs, kidneys, pancreas, or liver), accompanied by the organ function decompensation.
* Mental disorder.
* Contraindications for examination.
* Predicted unwillingness of the patient to follow the protocol of treatment and supervision, poor adherence to treatment.
* Patient's participation in any interventional/observational study at the present time.
* Patients who received venoactive drugs in the 4 weeks prior to Visit 0 (inclusion visit).